Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania

A. J. Breugom; E. Bastiaannet; P. G. Boelens; L. H. Iversen; A. Martling; R. Johansson; T. Evans; Sarah Lawton; K. M. O'Brien; E. Van Eycken; R. Janciauskiene; G. J. Liefers; A. Cervantes; V. E.P.P. Lemmens; C. J.H. Van De Velde

doi:10.1016/j.ejca.2016.04.017

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania

A. J. Breugom, E. Bastiaannet, P. G. Boelens, L. H. Iversen, A. Martling, R. Johansson, T. Evans, Sarah Lawton, K. M. O'Brien, E. Van Eycken, R. Janciauskiene, G. J. Liefers, A. Cervantes, V. E.P.P. Lemmens, C. J.H. Van De Velde^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

22 Citations (Scopus)

Abstract

Background The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries. Methods Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries. Results Overall, 59,154 patients were included. The proportion of patients receiving adjuvant chemotherapy ranged from 7.1% to 29.0% (p < 0.001). Compared with NL, a better adjusted relative survival was observed in SE (stage II: relative excess risks (RER) 0.53, 95% confidence interval (CI) 0.44-0.64; p < 0.001), and BE (stage II: RER 0.84, 95% CI 0.76-0.92; p < 0.001), and in IE for patients with stage IIA disease (RER 0.80, 95% CI 0.65-0.98; p = 0.03). Conclusion The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. Compared with NL, SE and BE showed an improved adjusted relative survival for stage II disease, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer.

Original language	English
Pages (from-to)	110-117
Number of pages	8
Journal	European Journal of Cancer
Volume	63
DOIs	https://doi.org/10.1016/j.ejca.2016.04.017
Publication status	Published - 1 Aug 2016

Bibliographical note

Funding Information:
National datasets from the Netherlands Cancer Registry (NL), the Danish Colorectal Cancer Group database (DK), the Swedish Colorectal Cancer Registry (SE), the English National Cancer Registration Service database Cancer Analysis System (ENG), the National Cancer Registry Ireland (IE), and the Belgian Cancer Registry (BE) were included. Moreover, we obtained single-centre data from the Hospital of Lithuanian University of Health Sciences Kaunas Clinics (LT).

Funding Information:
EURECCA was funded by the European Society of Surgical Oncology (ESSO) . The funding source had no role in the study design, data collection, analysis, interpretation of the data, writing of the manuscript, or the decision to publish.

Publisher Copyright:
© 2016 Elsevier Ltd. All rights reserved.

Keywords

Adjuvant chemotherapy
Colon cancer
International comparison
Population-based
Stage II
Surgery

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.ejca.2016.04.017

Cite this

Breugom, A. J., Bastiaannet, E., Boelens, P. G., Iversen, L. H., Martling, A., Johansson, R., Evans, T., Lawton, S., O'Brien, K. M., Van Eycken, E., Janciauskiene, R., Liefers, G. J., Cervantes, A., Lemmens, V. E. P. P., & Van De Velde, C. J. H. (2016). Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. European Journal of Cancer, 63, 110-117. https://doi.org/10.1016/j.ejca.2016.04.017

@article{fccb3378e20c4f68bf4e6dafd9b01a21,

title = "Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania",

abstract = "Background The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries. Methods Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries. Results Overall, 59,154 patients were included. The proportion of patients receiving adjuvant chemotherapy ranged from 7.1% to 29.0% (p < 0.001). Compared with NL, a better adjusted relative survival was observed in SE (stage II: relative excess risks (RER) 0.53, 95% confidence interval (CI) 0.44-0.64; p < 0.001), and BE (stage II: RER 0.84, 95% CI 0.76-0.92; p < 0.001), and in IE for patients with stage IIA disease (RER 0.80, 95% CI 0.65-0.98; p = 0.03). Conclusion The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. Compared with NL, SE and BE showed an improved adjusted relative survival for stage II disease, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer.",

keywords = "Adjuvant chemotherapy, Colon cancer, International comparison, Population-based, Stage II, Surgery",

author = "Breugom, {A. J.} and E. Bastiaannet and Boelens, {P. G.} and Iversen, {L. H.} and A. Martling and R. Johansson and T. Evans and Sarah Lawton and O'Brien, {K. M.} and {Van Eycken}, E. and R. Janciauskiene and Liefers, {G. J.} and A. Cervantes and Lemmens, {V. E.P.P.} and {Van De Velde}, {C. J.H.}",

note = "Funding Information: National datasets from the Netherlands Cancer Registry (NL), the Danish Colorectal Cancer Group database (DK), the Swedish Colorectal Cancer Registry (SE), the English National Cancer Registration Service database Cancer Analysis System (ENG), the National Cancer Registry Ireland (IE), and the Belgian Cancer Registry (BE) were included. Moreover, we obtained single-centre data from the Hospital of Lithuanian University of Health Sciences Kaunas Clinics (LT). Funding Information: EURECCA was funded by the European Society of Surgical Oncology (ESSO) . The funding source had no role in the study design, data collection, analysis, interpretation of the data, writing of the manuscript, or the decision to publish. Publisher Copyright: {\textcopyright} 2016 Elsevier Ltd. All rights reserved.",

year = "2016",

month = aug,

day = "1",

doi = "10.1016/j.ejca.2016.04.017",

language = "English",

volume = "63",

pages = "110--117",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Elsevier Ltd.",

}

Breugom, AJ, Bastiaannet, E, Boelens, PG, Iversen, LH, Martling, A, Johansson, R, Evans, T, Lawton, S, O'Brien, KM, Van Eycken, E, Janciauskiene, R, Liefers, GJ, Cervantes, A, Lemmens, VEPP & Van De Velde, CJH 2016, 'Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania', European Journal of Cancer, vol. 63, pp. 110-117. https://doi.org/10.1016/j.ejca.2016.04.017

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania. / Breugom, A. J.; Bastiaannet, E.; Boelens, P. G. et al.
In: European Journal of Cancer, Vol. 63, 01.08.2016, p. 110-117.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania

AU - Breugom, A. J.

AU - Bastiaannet, E.

AU - Boelens, P. G.

AU - Iversen, L. H.

AU - Martling, A.

AU - Johansson, R.

AU - Evans, T.

AU - Lawton, Sarah

AU - O'Brien, K. M.

AU - Van Eycken, E.

AU - Janciauskiene, R.

AU - Liefers, G. J.

AU - Cervantes, A.

AU - Lemmens, V. E.P.P.

AU - Van De Velde, C. J.H.

N1 - Funding Information: National datasets from the Netherlands Cancer Registry (NL), the Danish Colorectal Cancer Group database (DK), the Swedish Colorectal Cancer Registry (SE), the English National Cancer Registration Service database Cancer Analysis System (ENG), the National Cancer Registry Ireland (IE), and the Belgian Cancer Registry (BE) were included. Moreover, we obtained single-centre data from the Hospital of Lithuanian University of Health Sciences Kaunas Clinics (LT). Funding Information: EURECCA was funded by the European Society of Surgical Oncology (ESSO) . The funding source had no role in the study design, data collection, analysis, interpretation of the data, writing of the manuscript, or the decision to publish. Publisher Copyright: © 2016 Elsevier Ltd. All rights reserved.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries. Methods Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries. Results Overall, 59,154 patients were included. The proportion of patients receiving adjuvant chemotherapy ranged from 7.1% to 29.0% (p < 0.001). Compared with NL, a better adjusted relative survival was observed in SE (stage II: relative excess risks (RER) 0.53, 95% confidence interval (CI) 0.44-0.64; p < 0.001), and BE (stage II: RER 0.84, 95% CI 0.76-0.92; p < 0.001), and in IE for patients with stage IIA disease (RER 0.80, 95% CI 0.65-0.98; p = 0.03). Conclusion The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. Compared with NL, SE and BE showed an improved adjusted relative survival for stage II disease, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer.

AB - Background The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries. Methods Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries. Results Overall, 59,154 patients were included. The proportion of patients receiving adjuvant chemotherapy ranged from 7.1% to 29.0% (p < 0.001). Compared with NL, a better adjusted relative survival was observed in SE (stage II: relative excess risks (RER) 0.53, 95% confidence interval (CI) 0.44-0.64; p < 0.001), and BE (stage II: RER 0.84, 95% CI 0.76-0.92; p < 0.001), and in IE for patients with stage IIA disease (RER 0.80, 95% CI 0.65-0.98; p = 0.03). Conclusion The proportion of patients with stage II colon cancer receiving adjuvant chemotherapy varied largely between seven European countries. No clear linear pattern between adjuvant chemotherapy and adjusted relative survival was observed. Compared with NL, SE and BE showed an improved adjusted relative survival for stage II disease, and IE for patients with stage IIA disease only. Further research into selection criteria for adjuvant chemotherapy could eventually lead to individually tailored, optimal treatment of patients with stage II colon cancer.

KW - Adjuvant chemotherapy

KW - Colon cancer

KW - International comparison

KW - Population-based

KW - Stage II

KW - Surgery

UR - http://www.scopus.com/inward/record.url?scp=84974632949&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2016.04.017

DO - 10.1016/j.ejca.2016.04.017

M3 - Article

C2 - 27299663

AN - SCOPUS:84974632949

SN - 0959-8049

VL - 63

SP - 110

EP - 117

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this